rociletinib
Small moleculeexperimental
Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer. In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency. — Wikipedia
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2012 (NCT01526928)
Timeline
Indications
Mechanism of action
EGFR inhibitor
Irreversible inhibitor, EGFR T790M mutant selective
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(N4CCN(C(C)=O)CC4)cc3OC)ncc2C(F)(F)F)c1- Mol. weight
- 555.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRociletinib ↗
- ChEMBLCHEMBL3545308 ↗
Also known as
- avl-301
- avl-301
- cnx-419
- cnx-419
- co-1686
- co-1686
- co-1686
- rociletinib
- rociletinib
- rociletinib
- rociletinib
- rociletinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02705339 | Phase 2 | May 1, 2016 | Clovis Oncology, Washington University in St. Louis |
| NCT02630186 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2016 | Clovis Oncology, Genentech |
| NCT02547675 | N/A | Sep 10, 2015 | Clovis Oncology |
| NCT02580708 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2015 | Clovis Oncology, Novartis |
| NCT02322281 | Phase 3 | Feb 1, 2015 | Clovis Oncology |
| NCT02186301 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2014 | Clovis Oncology |
| NCT02147990 | Phase 2 | Apr 1, 2014 | Clovis Oncology |
| NCT01526928 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2012 | Clovis Oncology |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clovis Oncology | For profit | 8 | 7 | 3 | 2012 |
| Genentech | For profit | 1 | 0 | 1 | 2016 |
| Novartis | For profit | 1 | 0 | 1 | 2015 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1